Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: cell and gene therapy sector suffers from arrested development

April 19, 2021 5:15pm

… And “falling knives”

Pre-open indication performance: 7 HITs and 1 Miss

News: The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies (ADVM) < Believes Board’s Abject Failure to Exert Sufficient Oversight of Management Has Led to Significant Stockholder Value Destruction and Must Be Immediately Addressed <read more.

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

The Dow closed DOWN -123.04 points (-0.36%); the S&P closed DOWN -22.21 points (-0.53%) while the Nasdaq closed DOWN -137.58 points (-0.98%)

Henry’omics:

Indexes slipped and fell from record levels to start the week on Monday as the weakness weighed on the broader market.

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

Monday opened negative at 4/22, 1 flat and 1 acquired, stayed negative at the mid-day to 2/32, and 1 acquired, closing negative at 3/31 and 1 acquired;

RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: a dine and a dash scenario. A session of “irrational exuberance” or manic displacement” … https://www.regmedinvestors.com/articles/11871

Pre-open indication results: 7 HITs < Biostage (BSTG -$0.06 <was -$0.23 to $1.11> to $1.28 with 1,.60 shares traded <with a last minute 106 shares “pumped”); SELL/Falling Knife: bluebird bio (BLUE -$0.30), CRISPR Therapeutics (CRSP -$3.52), Editas Medicine (EDIT -$0.50), Intellia Therapeutics (NTLA -$3.12), Ultragenyx (RARE -$3.33), Vericel (VCEL -$3.85) and 1 MISS < BUY: Ionis Pharmaceuticals (IONS -$0.84)>

News (continued): The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies (ADVM)

Believes Board’s Abject Failure to Exert Sufficient Oversight of Management Has Led to Significant Stockholder Value Destruction and Must Be Immediately Addressed
Adverum Is Abusing the Corporate Machinery to Entrench Incumbent Directors and Disenfranchise Stockholders
Company Has Lost Confidence of Stockholders Through Persistent Mismanagement and Repeated Scientific, Communications and Capital Allocation Blunders
Read more: https://www.businesswire.com/news/home/20210419005877/en

There are clear winners and losers

Jumping with share pricing momentum:

Sage Therapeutics (SAGE), Adverum Biotechnologies (ADVM), Verastem (VSTM), to name 3 of the 3 inclining of the 35 covered

Hammered in today’s market:

ReNeuron (RENE.L), Ultragenyx (RARE), Vericel (VCEL), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) to name 5 of the 31 declining of the 35 covered

Key metrics:

Sector volume was LOW with 0 of the 3-upside having higher than the 3-month average volume with the volume of 3 of 31 downside having higher than the 3-month average volume;

Monday’s percentage (%) of the 3-upside were +0.55% (SAGE) to +1.13% (ADVM) while the 31-downside ranges from -0.02% (GBT) to -6.57% (VCEL);

Monday’s (3 of 3) incline

Sage Therapeutics (SAGE +$0.41 after Friday’s -$0.86);
Adverum Biotechnologies (ADVM +$0.10);
Verastem (VSTM +$0.02);

Monday’s (10 of 31) decliners:

ReNeuron (RENE.L -$5.00 after Friday’s +$4.50);
Vericel (VCEL -$3.85 after Friday’s +$0.64);
CRISPR Therapeutics (CRSP -$3.52 after Friday’s -$5.29);
Ultragenyx (RARE -$3.33 after Friday’s -$0.86);
Intellia Therapeutics (NTLA -$3.12 after Friday’s -$4.32);
Fate Therapeutics (FATE -$1.52 after Friday’s -$3.23);
Alnylam Pharmaceuticals (ALNY -$1.48);
BioLife Solutions (BLFS -$1.46 after Friday’s +$0.47);
AxoGen (AXGN -$1.05 after Friday’s -$0.65);
uniQure NV (QURE -$0.99 after Friday’s -$1.40);

Closing: 1- Stemline Therapeutics (STML – acquired)

Sentiment and COVID-19:

White House chief medical advisor Dr. Anthony Fauci said he expects the U.S. will resume administration of the Johnson & Johnson vaccine. The Food and Drug Administration asked states last week to temporarily halt using the single dose vaccine “out of an abundance of caution” after six women developed a rare blood-clotting disorder. <CNBC>

COVID Data Tracker <Million>:

Monday 31,4 M cases,
Monday’s death rate totaled 563,980 <Johns Hopkins University>
Monday vaccinations: 209 M

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday, the IBB closed down -1.10% and XBI closed down -2.15%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Monday was up +1.05 points or +6.46% at 17.30

Upside volume: low

Monday: 0 out of the 3-upside had higher than the 3-month average volume;

Downside volume: low

Monday: 3 out of the 31-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

Monday’s percentage (%) of the 3-upside were +0.55% (SAGE) to +1.13% (ADVM) while the 31-downside ranges from -0.02% (GBT) to -6.57% (VCEL);

April, the beginning of Q2/21:

Monday (4/19) closed negative with 3 advancers, 31 decliners and 1 acquired

The BOTTOM LINE: As I had stated, “I have NOT been buying into sustainability … I have been wrong yet in a few sessions, I have been righter, more often as mini-rotations have made the sector rally over bought, despite the 3-session uptrend.

Q1/21 earnings are being announced, Alnylam Pharmaceuticals (ANY) on Thursday, 4/29, AxoGen (AXGN) on Wednesday, 5/5 and Athersys (ATHX) on Thursday, 5/6.

Sector momentum remains “sketchy” and these depressed pricing guarantees more uncertainty and risks but, some rebounds.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

My time frame of measurement is Friday to Friday and been proved right again, don’t get complacent …

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.